You’re reading a copy of this week’s edition of the free New Cannabis Ventures weekly newsletter, which we have been publishing since October 2015.
Sign up to receive a copy in your inbox each Sunday morning.
This was an extremely tough week for investors and operators in the Canadian cannabis sector. We all knew that the roll out of legalization in Canada is highly flawed given the lack of retail distribution, but the full extent of the weakness was finally revealed, with the largest of the licensed producers (LPs) revealing abysmal numbers for the most part. While Tilray and Sundial were able to grow sequentially, Aurora Cannabis, Canopy Growth and Supreme Cannabis suffered double-digit percentage declines in the September quarter compared to the June quarter, with Organigram also pre-announcing a large decline sequentially from its Q3 to its Q4.
The narrative is consistent across all of the LPs: The number of stores in Ontario is insufficient. The province has a population of almost 15 million, yet there are fewer than three dozen stores. In Toronto, the largest city, there are only 10 stores open at this time in the entire metropolitan area. Contrast that with Chicago, a city similar in size, which had a lottery on Friday in advance of Illinois legalizing. The stores won’t all be open on day 1, as the winners need to secure locations, but the city has awarded 31 dispensary permits. Unlike Ontario, which had minimal qualifications required to enter its lottery, all of the Chicago lottery participants were already operating medical dispensaries and will hit the ground running. Additionally, the city expects to double the number of stores quickly.
While this past week saw selling across the sector due to the disappointing results from the LPs, which continue to struggle with profitability as well, the coming week is likely to change the tone as the reporting shifts to American multi-state operators (MSOs). We will see results from the three largest MSOs in terms of revenue, and it’s likely that the very positive trends from the first half of the year persist.
Trulieve is expected to generate Q3 revenue of $66 million, which would represent sequential growth of 14%. The company has exceeded expectations in each of the four prior quarters, its entire history as a public company, and it is generating huge profits from its Florida operations. Curaleaf could surpass Trulieve, as it is expected to generate $66.5 million in revenue, growth of 37% over Q2. Though, it has missed estimates in the past two quarters. Finally, Green Thumb Industries is expected to grow 37% from Q2 to $61.2 million. It has exceeded the consensus in the past three quarters. Perhaps investors will take notice that the revenue from these companies, if they are anywhere close to the expectations, will exceed those of largest Canadian LPs.
Investors are just beginning to pick up on the divergence in near-term prospects between the MSOs and large LPs. The chart below compares the three largest MSOs in terms of revenue with the largest LPs as measured by the Canadian Cannabis LP Tier 1 Index (in blue) over the past six months:
Until late August, the large LPs were tracking with the large MSOs, but, since then, there has been a divergence, which became more extreme last week as each of the large MSOs increased while the LPs sold off sharply.
Cannabis investors want to see growth, and the Canadian LPs aren’t yet delivering results that inspire investors. We think that will change in the next couple of quarters as fundamentals improve in Canada in Q1 with the advent of new products and better retail distribution. Fortunately, investors will likely be excited in the near-term as the MSOs produce the kind of near-term growth they seek.
In August 2013, CNN aired a documentary featuring Charlotte Figi, whose well-being had significantly improved after the use of the Stanley brothers’ customized extract. Over the last decade, the Stanley Brothers and the Company have evolved from the proprietary development of a single industrial hemp strain, to a market leader in the production and distribution of innovative hemp-based, cannabidiol wellness products.
Get up to speed by visiting the Charlotte’s Web Holdings Investor Dashboard that we maintain on their behalf as a client of New Cannabis Ventures. Click the blue Follow Company button in order to stay up to date with their progress.
New Cannabis Ventures publishes curated articles as well as exclusive news. Here is some of the most interesting business content from this week:
- Acreage Holdings Revenue Increases 307% to $22.4 Million
- Aurora Cannabis Generates $70.8 Million Cannabis Revenue in Q1 and Announces Convertible Note Settlement Plan
- Guest Post: BDS Analytics Details Cannabis Market Trends in 6 States During September
- Charlotte’s Web Q3 Revenue Increases 42% to $25.1 Million
- Cresco Labs Reduces Origin House Acquisition Price
- Cronos Group Q3 Revenue Increases to $12.7 Million
- GrowGeneration Q3 Revenue Increases 159% to $21.8 Million
- MediPharm Labs Q3 Revenue Increases 38% From Q2 to $43.4 Million
- MedMen Chops Assets and Headcount to Improve Profitability
- Organigram Pre-Announces Q4 Revenue at $16.3 Million
- Sundial Growers Reports $28 Million Cannabis Revenue in Q3
- Supreme Cannabis Reports $11.4 Million Quarterly Revenue and Secures $90 Million BMO Credit Facility
- Exclusive: This Former NBA Player Scores Big with His Cannabis Brand and Opens the Door for Minority Ownership
- Tilray Generates $51.1 Million Revenue in Q3
- Write-Downs Reduce Canopy Q2 Revenue to $76.6 Million
To get real-time updates download our free mobile app for Android or Apple devices, like our Facebook page, or follow Alan on Twitter. Share and discover industry news with like-minded people on the largest cannabis investor and entrepreneur group on LinkedIn.
Get ahead of the crowd! If you are a cannabis investor and find value in our Sunday newsletters, subscribe to 420 Investor, Alan’s comprehensive stock due diligence platform since 2013. Gain immediate access to real-time and in-depth information and market intelligence about the publicly traded cannabis sector, including daily videos, weekly chats, model portfolios, a community forum and much more.
Use the suite of professionally managed NCV Cannabis Stock Indices to monitor the performance of publicly-traded cannabis companies within the day or over longer time-frames. In addition to the comprehensive Global Cannabis Stock Index, we offer a family of indices to track Canadian licensed producers as well as the American Cannabis Operator Index.
View the Public Cannabis Company Revenue & Income Tracker, which ranks the top revenue producing cannabis stocks that generate industry sales of more than US$7.5M per quarter.
Stay on top of some of the most important communications from public companies by viewing upcoming cannabis investor earnings conference calls.
Discover upcoming new listings with the curated Cannabis Stock IPOs and New Issues Tracker.
Find your place in the cannabis industry by visiting our Careers and Jobs Page and learn which companies are hiring aggressively.
Alan & Joel